Home > Insider Trading > Filing (0001493152-22-035779)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1394319	Tracon Pharmaceuticals Inc.	TCON	Biological Products, (No Disgnostic Substances) (2836)	342037594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1595855	Opaleye Management Inc.	One Boston Place, 26Th Floor Boston MA 02108		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Acquisiton	2022-12-14	140,000	$1.26	4,150,000	No	4	P	Indirect	By Opaleye, L.P.
Common Stock, Par Value $0.001 Per Share	Acquisiton	2022-12-14	27,500	$1.24	440,000	No	4	P	Indirect	By Managed Account.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Opaleye, L.P.
No	4	P	Indirect	By Managed Account.

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Prefunded Warrants	$0.01	2020-08-27	2030-08-27	1,889,513	1,667,974	Indirect
Common Stock	Prefunded Warrants	$0.01	2020-08-31	2030-08-31	1,358,593	1,358,593	Indirect
Common Stock	Prefunded Warrants	$0.01	2022-06-21	2032-06-21	2,205,018	2,205,018	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2030-08-27	1,889,513	1,667,974	Indirect
2030-08-31	1,358,593	1,358,593	Indirect
2032-06-21	2,205,018	2,205,018	Indirect

Footnotes

Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
The prices reported above reflects the weighted average purchase price. These transactions were executed in multiple trades between $1.14 and $1.34. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.